All News

3 February 2007

Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot PsoriasisAntibodies

2 February 2007

Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26Antibodies

26 January 2007

Amgen’s Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 BillionAntibodies

26 January 2007

Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin’s LymphomaAntibodies

25 January 2007

First Actemra multinational phase III trial demonstrates significant improvement in signs and symptoms of rheumatoid arthritisAntibodies

25 January 2007

Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal AntibodyAntibodies

25 January 2007

Lucentis receives approval in the European Union – the first drug to improve vision in patients with wet AMD, a leading cause of blindnessAntibodies

24 January 2007

Medarex and Compugen Announce Therapeutic Antibody Co-Development AgreementAntibodies

18 January 2007

XOMA and Schering-Plough Add New Programs to Antibody CollaborationAntibodies

17 January 2007

Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II ‘Proof-of- Concept’ Clinical TrialAntibodies

17 January 2007

Oxford Biomedica Announces Publication Of Avian Transgenic Results In Leading U.S. Scientific JournalAntibodies

17 January 2007

Trubion Announces Completion of Enrollment and Dosing of Patients in Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid ArthritisAntibodies

16 January 2007

4- Antibody AG Closes CHF 17 Million Series A Financing, Bringing the Total Series A Financing to CHF 23 Million ($ 18.5Million)Antibodies

13 January 2007

BioInvent enters collaboration with Genentech to develop and commercialize BioInventÂ´s proprietary antibody for the potential treatment of cardiovascular diseasesAntibodies

12 January 2007

Immuno-Biological Laboratories Co., Ltd. and Intellect Neurosciences, Inc. Enter into Humanized Monoclonal Antibodies Development Agreement for the Treatment of Alzheimer’s DiseaseAntibodies

11 January 2007

ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal CancerAntibodies

11 January 2007

Organon and the Academic Medical Center jointly develop novel treatment of rheumatoid arthritisAntibodies

10 January 2007

BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401) Enhanced Using Potelligent(TM) TechnologyAntibodies

9 January 2007

Antibody-Company f-star Raises EUR1.5 Million in Seed Financing Round From Atlas VentureAntibodies

9 January 2007

Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) For Treatment Of Allergy Disorders To iCO TherapeuticsAntibodies

9 January 2007

Cytochroma Inc. and aOvaTechnologies, Inc., Sign License Agreement.Antibodies

9 January 2007

Protherics submits DigiFab(TM) New Drug Submission in CanadaAntibodies

9 January 2007

Seattle Genetics to Present at the JPMorgan Annual Healthcare ConferenceAntibodies

9 January 2007

Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40Antibodies

9 January 2007

Ablynx and Boehringer Ingelheim sign $265 million research and licensing agreement to develop new Alzheimer’s treatmentsAntibodies

6 January 2007

DSM Biologics and Crucell Announce PER.C6(R) Licensing Agreement with Biotecnol SA for Antibody ProductionAntibodies

6 January 2007

Helix BioPharma Corp. signs L-DOS47 manufacturing agreement with BioVectra dclAntibodies

5 January 2007

Genentech Announces Positive Results from a Randomized Phase II Study of Pertuzumab in Combination with Gemcitabine for Advanced Ovarian CancerAntibodies

5 January 2007

Raven Biotechnologies, Inc. And Wyeth (WYE) Partner To Evaluate And DevelopAntibodies

5 January 2007

Medarex Announces Enrollment Complete in Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial for Metastatic MelanomaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

5T4-Targeted Immunotherapy Candidates Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis